The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

• DOI: 10.1002/ijc.25423
• Publication Date: 2010-04-28T19:08:33Z
• Authors: Markus M. Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O. Kolesnik; Vladimir V. Ivanc...; Alexander S. Dudn...; Birute Aleknaviciene; Arturas Razbadauskas; Martin Gore; Elena Ganea‐Motan; Tudor Ciuleanu; Pauline Wimberger; Alexander Schmittel; Barbara Schmalfeldt; Alexander Burges; Carsten Bokemeyer; Horst Lindhofer; Angelika Lahr; Simon L. Parsons
• Keywords: Adult; Aged, 80 and over; 0301 basic medicine; Medizin; Ascites; Middle Aged; Combined Modality Therapy; Drug Administration Schedule; 3. Good health; 03 medical and health sciences; Antibodies, Bispecific; Cancer Therapy; Humans; Paracentesis; Neoplasms, Glandular and Epithelial; Aged

AbstractMalignant ascites is a common manifestation of advanced cancers, and treatment options are limited. The trifunctional antibody catumaxomab (anti‐epithelial cell‐adhesion molecule x anti‐CD3) represents a targeted immunotherapy for the intraperitoneal (i.p.) treatment of malignant ascites secondary to epithelial cancers. In this phase II/III trial (EudraCT 2004‐000723‐15; NCT00836654), cancer patients (n = 258) with recurrent symptomatic malignant ascites resistant to conventional chemotherapy were randomized to paracentesis plus catumaxomab (catumaxomab) or paracentesis alone (control) and stratified by cancer type (129 ovarian and 129 nonovarian). Catumaxomab was administered as an i.p. infusion on Days 0, 3, 7 and 10 at doses of 10, 20, 50 and 150 μg, respectively. The primary efficacy endpoint was puncture‐free survival. Secondary efficacy parameters included time to next paracentesis, ascites signs and symptoms and overall survival (OS). Puncture‐free survival was significantly longer in the catumaxomab group (median 46 days) than the control group (median 11 days) (hazard ratio = 0.254: p < 0.0001) as was median time to next paracentesis (77 versus 13 days; p < 0.0001). In addition, catumaxomab patients had fewer signs and symptoms of ascites than control patients. OS showed a positive trend for the catumaxomab group and, in a prospectively planned analysis, was significantly prolonged in patients with gastric cancer (n = 66; 71 versus 44 days; p = 0.0313). Although adverse events associated with catumaxomab were frequent, they were manageable, generally reversible and mainly related to its immunologic mode of action. Catumaxomab showed a clear clinical benefit in patients with malignant ascites secondary to epithelial cancers, especially gastric cancer, with an acceptable safety profile.